还没做过化疗，EGFR是野生型的病友一定要去做ALK的检测

jzjqian 发表于 2012-7-25 15:45

                               
登录/注册后可看大图

请教，像我这样的，手术22个月了，还能去原手术医院拿到病理作EGFR检查么？

0 S8 z. C9 q$ p/ o2 G- R可以，但要有针对性，

请问，肺鳞癌，只做过一次化疗，骨髓抑制严重，后吃特罗凯4个月基本无效，可以参加实验组吗？

不可以了,要没做过任何治疗的,包括化疗和靶向药

Concomitant EGFR mutation and EML4-ALK gene fusion in non-small cell lung cancer.  Print this page  
, R# Y+ w) D% y+ F& o1 @: O
2 }: P3 H) F* t9 g; r; |! p$ V
Sub-category:
2 L. D' d; Z& w+ C  D5 EMolecular Targets
' o3 u" M: ^' p% H
0 e# {" z7 w6 i& P( U( y" _* l2 }
% A( x# g- c3 @# c6 mCategory:
Tumor Biology


+ y. K; L5 T8 J0 ^% gMeeting:
% J; W& O$ t0 p8 ]$ `6 k* S! _2011 ASCO Annual Meeting
' g2 ?$ X* M& r; |/ {
" E9 L7 D' @+ r, z- m! D! H
0 u" U3 J6 p1 d! n& HSession Type and Session Title:
: s4 E+ a1 e, r7 lPoster Discussion Session, Tumor Biology
% d8 N5 W: ]6 u2 ^& V7 p/ [
* Z! d# g- Q. A. q, }. Z( |
2 |$ X& C1 |% t! NAbstract No:
10517


Citation:
J Clin Oncol 29: 2011 (suppl; abstr 10517)

* n% }* ]) [3 v; e0 d* |
Author(s):
/ _8 r  @0 h  u" R: {" d- {J. Yang, X. Zhang, J. Su, H. Chen, H. Tian, Y. Huang, C. Xu, Y. L. Wu; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China; Guangdong Lung Cancer Institute, Medical Research Center of Guangdong General Hospital, Guangzhou, China; Guangdong Lung Cancer Institute, Guangzhou, China; Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, Guangzhou, China
/ D8 B( L+ {1 g  ~8 I& _# O+ `

, B' n  G8 {  g5 g8 k# y; Z
0 O- E# ]6 F8 P% R  OAbstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy are designated with a caret symbol (^) here and in the printed Proceedings.
# U4 D9 S! G. ?- ]2 W" M6 V
4 f9 r( c8 i6 w" i, N7 e' f! UAbstract Disclosures

. Q1 O' E6 g. W* j" QAbstract:

/ r7 e, d: R: }5 z' J
, U0 E% V' a" \* a! b$ g3 eBackground: The fusion of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein-like 4 (EML4) and epidermal growth factor receptor (EGFR) mutations are considered mutually exclusive. Advanced non-small cell lung cancer (NSCLC) patients with EML4-ALK did not benefit from EGFR tyrosine kinase inhibitors (TKIs). Methods: Multiplex reverse transcriptase-polymerase chain reaction (RT-PCR) followed by sequencing was performed for EML4-ALK fusion status detection. EGFR and KRAS mutations were determined by direct DNA sequencing. Positive results of EML4-ALK fusion were also confirmed by RACE-coupled PCR sequencing. Results: From April 2010 to January 2011, 412 patients (398 with NSCLC; 14 with SCLC) were tested for mutation status of EGFR, KRAS and EML4-ALK respectively. Frequency of EML4-ALK fusion was 10.6% (42/398) in NSCLC patients. No patients with SCLC were found to have positive EML4-ALK fusion. Frequency of concomitant EGFR and EML4-ALK gene mutations was 1.0% (4/398) in NSCLC patients, and their variants of EML4-ALK gene mutations were Variant 1 (3 patients) and Variant 6 (1 patient); being never smokers, all of them were diagnosed with advanced (3 with stage †W and 1 with stage IIIB) adenocarcinoma harbouring wild type KRAS. Two female stage †W patients with double gene mutations (1 with L858R and Variant 1; 1 with exon19 deletion and Variant 6) received first-line gefitinib which is one kind of EGFR TKIs and achieved partial response. Conclusions: Though being rare events, NSCLC patients harbouring concomitant EGFR mutation and EML4-ALK gene fusion are sensitive to first-line EGFR TKIs. Whether they could also benefit from ALK inhibition after failure to EGFR TKIs warranted further investigation.

6 ?" O+ r1 X$ Z# M$ c/ u
) w6 ^. o) T% K# n- X# p

由吴一龙教授牵头的A80810029临床试验上周启动，初诊未治疗的晚期肺腺癌患者检测到ALK阳性，可参加一线crizotinib 对比力比泰+卡铂的临床研究，药物全部免费，即使分配到力比泰组，疾病进展之后可免费获得crizotinib.

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

boeun 发表于 2012-11-18 16:37

: i* T7 j" [6 N+ N4 V                               
登录/注册后可看大图

没有手术，只化疗过，现吃靶向药，未突变，alk未测，有机会入组吗？

化疗过的没机会了

平安！ 发表于 2012-7-20 11:20

" i3 z/ W  w3 C8 m                               
登录/注册后可看大图

9 x; ?# v  {, O# A易瑞沙、特罗凯有效的病人基本上可以断定ALK（-）。极其罕见EGFR、ALK同时突变的。
ALK一个指标医院要900多 ...

平安，真的没有希望吗？我弟弟虽然特罗凯有效，但是ＥＧＦＲ是野生型，不是突变啊。有没有必要去检测ＡＬＫ呢？
/ _. ^# m) w- G4 r% t
现在病情进展，快没招儿了。

好像想加入挺困难的

小地方没条件做啊